Back to dashboard
CommercialPrior AuthLow impact

Palynziq (pegvaliase-pqpz)

Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Pediatrics, Family Medicine·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi updated their prior authorization policy for Palynziq (pegvaliase-pqpz), a medication for phenylketonuria (PKU) patients. The policy requires strict criteria including age 12+, failed sapropterin trial, enrollment in REMS program, and specialist involvement.

Action Required

Action needed
Immediately: Billing team should verify prior authorization requirements for Palynziq (pegvaliase-pqpz) are documented in system for BCBS Mississippi patients. Ensure claims include documentation of PKU diagnosis, baseline phenylalanine levels >600 micromol/L, failed sapropterin trial, REMS program enrollment, and specialist involvement. Claims without proper prior authorization will be denied.